AGRF: Bringing Olink® Next Generation Proteomic Technology to Australia.

AGRF is thrilled to announce the introduction of the Olink Explore high throughput platform to our fleet of cutting-edge technologies, bringing the most advanced proteomic technology to Australia and positioning AGRF as a truly multi-omics destination. This strategic move promises to be a game changer in precision medicine, offering researchers a full multi-omics profile of patient and biobank samples.

“We are very excited to be expanding our state-of-the-art genomic instrumentation to include the latest in next generation proteomic technology.” says Dr Cath Moore, Chief Scientific Officer at AGRF.  “We will be the first in Australia to provide the Olink Explore HT and Explore 3072 platforms, revolutionising disease biology and drug discovery.”  The addition reinforces AGRF’s commitment to providing Australian researchers and industry with cutting-edge tools to accelerate scientific discovery.

The Olink technology, designed to measure proteins at scale, has been adopted by leading researchers globally. With the introduction of the Olink Explore platforms at AGRF, scientists will now have the capability to accurately measure over 5,400 proteins simultaneously using a single plasma sample. This groundbreaking technology opens a multitude of applications across therapeutic areas and enhances our understanding of molecular pathways in disease development, progression, and outcome.

The addition of the Olink technology will empower researchers to identify proteins and pathways likely to be causal in disease, paving the way for the development of new diagnostic mechanisms. This advancement marks a critical step towards bridging the gap between genes, proteins, and disease, facilitating a more comprehensive understanding of the molecular intricacies that drive various medical conditions.[1] 

By introducing Olink’s cutting-edge proteomic technology to Australia, AGRF is poised to play a pivotal role in progressing scientific research, unlocking new avenues in precision medicine, and empowering impactful discoveries.

About AGRF: AGRF is a not-for-profit organisation, powering Australian genomics through a national network of genomic services and expertise. As Australia’s premier provider of genomic services, AGRF is a key contributor to genomic innovation and development, providing local access to expertise, state-of-the-art technology and comprehensive support across a broad range of industries including biomedical, health, agriculture and environmental sectors.

About Olink: Olink Holding AB (publ) (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. To learn more about Olink, visit olink.com

[1] Empower Genomics with Proteomics, Olink white paper, viewed 17 January 2024.